Abstract
Background & Method: A series of thirty-one new 1-phthalazinones was designed and synthesized based on the well-known VEGFR inhibitor vatalanib. The obtained phthalazinones were screened for their cytotoxic activity against DLD-1 and LoVo (colon), and Panc-1 and Paca-2 (pancreas) cancer cell lines using MTT assay. The tested compounds revealed exceptionally promising cytotoxic activity against LoVo cell lines with IC50 ranges 0.18-780 nM.
Conclusion: Finally, these compounds were also found to be dual inhibitors of VEGFR-2 and EGFR in the in vitro enzyme assay with higher potency against the former (IC50 = 0.023-0.41 nM).
Keywords: Cytotoxicity, EGFR, 1-Phthalazinone, VEGFR-2, xenograft, Cancer.
Mini-Reviews in Medicinal Chemistry
Title:New 1-phthalazinone Scaffold based Compounds: Design, Synthesis, Cytotoxicity and Protein Kinase Inhibition Activity
Volume: 18 Issue: 20
Author(s): Nehad E. Abo-elmagd, Riham F. George, Manal A. Ezzat and Reem K. Arafa*
Affiliation:
- University of Science and Technology, Zewail City of Science and Technology, Cairo, 12588,Egypt
Keywords: Cytotoxicity, EGFR, 1-Phthalazinone, VEGFR-2, xenograft, Cancer.
Abstract: Background & Method: A series of thirty-one new 1-phthalazinones was designed and synthesized based on the well-known VEGFR inhibitor vatalanib. The obtained phthalazinones were screened for their cytotoxic activity against DLD-1 and LoVo (colon), and Panc-1 and Paca-2 (pancreas) cancer cell lines using MTT assay. The tested compounds revealed exceptionally promising cytotoxic activity against LoVo cell lines with IC50 ranges 0.18-780 nM.
Conclusion: Finally, these compounds were also found to be dual inhibitors of VEGFR-2 and EGFR in the in vitro enzyme assay with higher potency against the former (IC50 = 0.023-0.41 nM).
Export Options
About this article
Cite this article as:
Abo-elmagd E. Nehad , George F. Riham , Ezzat A. Manal and Arafa K. Reem *, New 1-phthalazinone Scaffold based Compounds: Design, Synthesis, Cytotoxicity and Protein Kinase Inhibition Activity, Mini-Reviews in Medicinal Chemistry 2018; 18 (20) . https://dx.doi.org/10.2174/1389557518666180903153254
DOI https://dx.doi.org/10.2174/1389557518666180903153254 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry Hydrodynamic Gene Delivery to the Liver: Theoretical and Practical Issues for Clinical Application
Current Gene Therapy Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Extracellular Superoxide and the Growth of Pancreatic Carcinoma
Current Cancer Therapy Reviews Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design MicroRNA-7 Regulates Insulin Signaling Pathway by Targeting IRS1, IRS2, and RAF1 Genes in Gestational Diabetes Mellitus
MicroRNA Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets The Therapeutic Potential of Microencapsulate Implants: Patents and Clinical Trials
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mitochondria-Targeted Antioxidant Peptide SS31 Protects the Retinas of Diabetic Rats
Current Molecular Medicine Biological and Pharmacological Activities of Carvacrol and Carvacrol Bearing Essential Oils
Current Pharmaceutical Design Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry Pharmacological Effects of Secondary Bile Acid Microparticles in Diabetic Murine Model
Current Diabetes Reviews Profiles of Two Glycaemia Modifying Drugs on the Expression of Rat and Human Sulfotransferases
Current Drug Metabolism Mimicking Microvascular Alterations of Human Diabetic Retinopathy: A Challenge for the Mouse Models
Current Medicinal Chemistry The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Genomic Instability and Cancer
Current Molecular Medicine